Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BI 1823911 + Midazolam |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BI 1823911 | BI-1823911|BI1823911 | KRAS G12C inhibitor 34 | BI 1823911 is a small molecule that selectively inhibits KRAS G12C, which may lead to inhibition of tumor cell proliferation and antitumor activity (Cancer Res 2021;81(13_Suppl):Abstract nr 1271). | |
Midazolam | Dormicum | Dea No. 2884 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04973163 | Phase I | BI 1823911 + Midazolam BI 1701963 + BI 1823911 | A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation | Active, not recruiting | USA | GBR | ESP | BEL | 0 |